Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG Fresenius for cGvHD Prophylaxis in Acute Leukemia
NCT00678275Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2006
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of grafalon in graft-versus-host disease (GVHD) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Cumulative Incidence of Chronic Graft-versus-Host Disease at 2 years. Started Oct 2006; status: completed.
02
Drugs
grafalon
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00678275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678275.